Epidemiology and Genomics Research
CANCER EPIDEMIOLOGY MATTERS E-NEWS
JANUARY 2018

Follow us on Twitter
January 2018 Features Announcements
Contact Us
FOAsFunding
 Opportunity Announcements
PAR-18-583 (X01)
Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program
Application Due Date: March 22, 2018
Expiration Date: March 23, 2018

PAR-18-552 (U01)
Partnership for Aging and Cancer Research
Application Due Date: June 8, 2018
Expiration Date: June 9, 2018

PA-18-573 (Parent SBIR [R43/R44])
PA-18-574  (Parent SBIR [R43/R44])
PHS 2018-02 Omnibus Solicitation of the NIH for Small Business Innovation Research Grant Applications
Application Due Date: Standard dates apply.
Expiration Date: April 6, 2019

PA-18-575 (Parent STTR [R41/R42])
PA-18-576  (Parent STTR [R41/R42])
PHS 2018-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications
Application Due Date: Standard dates apply.
Expiration Date: April 6, 2019

PA-16-288 (Admin Supp)
Research Supplements to Promote Diversity in Health-Related Research
Application Due Date: Due dates may vary by awarding IC.
Expiration Date: September 30, 2019

PAR-18-577 (U01)*
New Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases and Disorders
Application Due Dates: June 5, 2018, June 5, 2020
Expiration Date: June 6, 2020

PAR-18-539 (K01)
PAR-18-540 (K01)
International Research Scientist Development Award
Application Due Dates: March 7, 2018; March 7, 2019; March 6, 2020
Expiration Date: March 7, 2020

PA-18-531 (R03)
PA-18-532   (R21)
PA-18-529  (R01)
Early-life Factors and Cancer Development Later in Life
Application Due Date: Standard dates apply.
Expiration Date: January 8, 2021

PA-18-484 (Parent R01)
PA-18-345 (Parent R01)*
NIH Research Project Grant
Application Due Date: Standard dates apply.
Expiration Date: January 8, 2021

PAR-18-559 (R01)
Cancer Prevention and Control Clinical Trials Grant Program
Application Due Date: March 15, 2018, then Standard dates apply.
Expiration Date: January 8, 2021

PA-18-591 
(Parent Admin Supp)
Administrative Supplements to Existing NIH Grants and Cooperative Agreements
Application Due Date: Due dates may vary by awarding IC.
Expiration Date: January 26, 2021

PA-18-586 
(Admin Supp)
Research Supplements to Promote Diversity in Health-Related Research
Application Due Date: Due dates may vary by awarding IC.
Expiration Date: September 8, 2021

PA-18-592 
(Admin Supp)

Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers
Application Due Date: Due dates may vary by awarding IC.
Expiration Date: September 8, 2021

*NCI is not participating in this FOA
PolicyGrants Policy Announcements
NOT-OD-18-107
NIH Enforcement of Closeout Policies

NOT-OD-18-115
Maintaining Integrity in NIH Peer Review: Responsibilities and Consequence

NOT-OD-18-129
Revised: Notice of NIH's Interest in Diversity

NOT-OD-18-128
Grant Application Instruction Correction for Training Grants with Human Subjects Involvement
RFIRequests  for
Informatio n
All of Us Research Program Seeks Input on Research Priorities
Responses due: February 23, 2018

NOT-OD-18-110
Soliciting Input for the Tribal Health Research Office Strategic Plan (FY2018-2022)
Responses Due: February 4, 2018
JobJob Opportunities
Fellow Sought for Genomic Epidemiology

Cancer Research Training Award Fellowship in Office of the Director, Division of Cancer Control and Population Sciences
TrainingTraining Opportunities
Training Institute for Dissemination and Implementation Research in Cancer (TIDIRC)
Applications due: February 9, 2018
EventsUpcoming Webinars & Workshops
Gabriella Miller Kids First X01 Pre-Application Webinar (PAR-18-583)
February 8, 2018

Integrating Genome Sequencing in Health Care Systems: Evaluation, Implementation and Population Health Impact Webinar 
February 14, 2018

Pre-Application Webinar on NCI's Provocative Questions Relevant to Population Scientists
February 15, 2018

Director's Seminar Series - From Germline Genetics to Function: Making Sense of Genome-Wide Association Studies for Pancreatic Cancer Risk
March 9, 2018
BlogsBlog Posts
Further Refining Case Studies and FAQs about the NIH Definition of a Clinical Trial in Response to Your Questions
Dr. Michael Lauer
Open Mike

Reminder: Changes for January 25, 2018 Application Due Dates
Extramural Nexus

Ensuring Successful Implementation of the NIH Single IRB Policy: A Teamwork Approach
Office of Science Policy Blog
AboutAbout EGRP
The Epidemiology and Genomics Research Program (EGRP) in the Division of Cancer Control and Population Sciences (DCCPS) funds research in human populations to understand the causes of cancer and related outcomes.

The Program fosters interdisciplinary collaborations, as well as the development and use of resources and technologies to advance cancer research and translation of this research, which serve as the basis for clinical and public health interventions.
ContactContact Us
email: nciepimatters@mail.nih.gov
website: epi.grants.cancer.gov
twitter: twitter.com/NCIEpi
ResearchHighlights
Each year, staff in the Epidemiology and Genomics Research Program (EGRP) nominate and vote for manuscripts published by EGRP grantees that are deemed to have the greatest potential scientific and/or public health impact. The following publications were chosen for inclusion in the 2017 Research Highlights

Blood Cancer
Francis SS, Wallace AD, Wendt GA, Li L, Liu F, Riley LW, et al. In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia. Blood. 2017 Mar 23;129(12):1680-1684.

Breast Cancer
Hoffman JD, Graff RE, Emami NC, Tai CG, Passarelli MN, Hu D, et al.  Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated with breast cancer risk. PLoS Genet. 2017 Mar 31;13(3):e1006690.

Chollet-Hinton L, Olshan AF, Nichols HB, Anders CK, Lund JL, Allott EH, et al. Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium. Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1722-1729.

Clarke CA, Canchola AJ, Moy LM, Neuhausen SL, Chung NT, Lacey JV Jr, Bernstein L. Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study. Breast Cancer Res. 2017 May 1;19(1):52.

Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci . Nature . 2017 Nov 2;551(7678):92-94.

Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, et al. Identification of ten variants associated with risk of estrogen-receptor negative breast cancer. Nat Genet. 2017 Dec;49(12):1767-1778.

Lung Cancer
McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet. 2017 Jul;49(7):1126-1132.

Multiple Cancers
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al.  Risks of Breast, Ovarian, Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers JAMA . 2017 Jun 20;317(23):2402-2416.

Lindström S, Finucane H, Bulik-Sullivan B, Schumacher FR, Amos CI, Hung RJ, et al. Quantifying the Genetic Correlation between Multiple Cancer Types. Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1427-1435.

Survivorship
Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017 Dec 9;390(10112):2569-2582.

Research Highlights nominees are drawn from an annual compilation of grantees' manuscripts. Please  see the article at the bottom of this newsletter highlighting additional reasons to alert your EGRP Program Director of publications supported by NCI funds.
QuickTip
Grantees with at least one year remaining on their grant who want to expand their project's scope may request a revision (also known as a competitive revision, competing revision, or a competitive supplement). Please note that a revision is neither an administrative supplement (a noncompeting award that provides additional funding to a currently funded grant to meet increased costs that are within the scope of the approved project) nor an application resubmission (an unfunded application that has been modified following initial review and resubmitted for new consideration). Any grantee interested in a revision must submit an application, which must undergo peer review and be selected for funding. 

Investigators may apply for revisions either through a revision-specific Funding Opportunity Announcement (FOA), or to the FOA to which the parent grant was submitted (or a reissuance of that FOA), as long as that FOA allows revision applications. Revisions may not extend beyond that grant's project period. Also, revisions do not restore funds that were part of standard grant reductions.

Below are some examples of NCI FOAs accepting revision applications.

Revision Applications to National Cancer Institute (NCI)-supported Awards to Include Research on the NCI's Provocative Questions
Applications due: June 28, 2018; October 30, 2018
Expiration date: October 31, 2018
To learn more about NCI's Provocative Questions awards, consider attending this Pre-Application Webinar on NCI's Provocative Questions Relevant to Population Scientists on February 15, 2018, 2:00 - 3:00 p.m. ET.

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research  
Applications Due: February 28, 2018; May 29, 2018; September 28, 2018
Expiration Date: September 29, 2018
For more information about revisions to an existing grant, visit https://grants.nih.gov/grants/competing-revisions.htm.
PublishingPublishing Soon? Let Us Know!

Each year, EGRP provides funding for hundreds of research grants, which results in numerous publications. EGRP would like to help you and your institution get the word out about your work; having advance notice of publication is important for planning purposes. There are several reasons sending a quick email to your EGRP Program Director (PD)--when your research is accepted for publication--is a good idea: 

If a study receives a great deal of attention in mass media, the media, patients, or advocates may contact NCI with questions. In these cases, it is helpful to have advance notice of publication so that NCI staff have time to become familiar with the study results and can be prepared to answer questions from the public.

When NCI has advance notice of publications, it may want to highlight research from its grantees via blog posts, social media, and coordination with news media outletsLarge-scale publicity efforts, however, require time to plan, so letting your PD know about any potentially newsworthy research results when they are accepted for publication is essential. 

EGRP may also use its @NCIEpi Twitter account  to spread the word about NCI-funded epidemiology and genomics research. Approximately 5,700 Twitter accounts receive updates from @NCIEpi, including scientists, government agencies, research organizations, students, advocates, and other NIH-affiliated accounts. 

Whether you are a new EGRP grantee or a seasoned investigator, it pays to let us know about your EGRP-funded research publications. So next time a journal article of yours is accepted, be sure to email your EGRP PD with the news!
  Epidemiology and Genomics Research ProgramDivision of Cancer Control and Population Sciences, National Cancer Institute | 9609 Medical Center Drive | 4 East, MSC 9763 | Bethesda | MD 20892


  Contact Us |   Privacy Policy |   Accessibility |   FOIA 

 

NIH... Turning Discovery Into Health®